Literature DB >> 7482389

INDANA: a meta-analysis on individual patient data in hypertension. Protocol and preliminary results.

F Gueyffier1, F Boutitie, J P Boissel, J Coope, J Cutler, T Ekbom, R Fagard, L Friedman, H M Perry, S Pocock.   

Abstract

The overall effect of antihypertensive drug treatment has been well documented. The proportion of patients who benefit varies according to their baseline cardiovascular risk, and is small for the majority of people treated. Some investigators propose limiting the treatment target population to patients at high cardiovascular risk, but several assumptions must be made to justify this procedure. The INDANA project is a meta-analysis based on individual patient data, and thus offers the opportunity to check the validity of these assumptions. Its main objective is to identify responders (and non-responders) in the drug treatment of hypertension. The rationale and methods for such an approach are presented here, with the solution for some technical problems. The conclusion of the data collection has shown that the project is feasible. The results of the main analysis should be available in 1996, and should contribute to the selection of responders and to the individualization of the treatment of hypertension.

Entities:  

Mesh:

Year:  1995        PMID: 7482389

Source DB:  PubMed          Journal:  Therapie        ISSN: 0040-5957            Impact factor:   2.070


  17 in total

1.  Identification of responders to a therapy: an example of validation of a predictive model.

Authors:  W Li; J P Boissel; M Cucherat; F Gueyffier; F Boutitie
Journal:  Eur J Epidemiol       Date:  1999-07       Impact factor: 8.082

2.  Models to predict cardiovascular risk: comparison of CART, multilayer perceptron and logistic regression.

Authors:  I Colombet; A Ruelland; G Chatellier; F Gueyffier; P Degoulet; M C Jaulent
Journal:  Proc AMIA Symp       Date:  2000

Review 3.  Prospectively designed overviews of recent trials comparing antihypertensive regimens based on different drug classes.

Authors:  N Chapman; B Neal
Journal:  Curr Hypertens Rep       Date:  2001-08       Impact factor: 5.369

Review 4.  [Blood pressure and the brain].

Authors:  A Hartmann; S Moskau
Journal:  Internist (Berl)       Date:  2005-05       Impact factor: 0.743

Review 5.  Pharmacotherapy for hypertension in adults aged 18 to 59 years.

Authors:  Vijaya M Musini; Francois Gueyffier; Lorri Puil; Douglas M Salzwedel; James M Wright
Journal:  Cochrane Database Syst Rev       Date:  2017-08-16

6.  A score for predicting risk of death from cardiovascular disease in adults with raised blood pressure, based on individual patient data from randomised controlled trials.

Authors:  S J Pocock; V McCormack; F Gueyffier; F Boutitie; R H Fagard; J P Boissel
Journal:  BMJ       Date:  2001-07-14

Review 7.  The Perindopril Protection Against Recurrent Stroke Study (PROGRESS): clinical implications for older patients with cerebrovascular disease.

Authors:  Yogini Ratnasabapathy; Carlene M M Lawes; Craig S Anderson
Journal:  Drugs Aging       Date:  2003       Impact factor: 3.923

8.  Virtual patients and sensitivity analysis of the Guyton model of blood pressure regulation: towards individualized models of whole-body physiology.

Authors:  Robert Moss; Thibault Grosse; Ivanny Marchant; Nathalie Lassau; François Gueyffier; S Randall Thomas
Journal:  PLoS Comput Biol       Date:  2012-06-28       Impact factor: 4.475

9.  Treatment of high blood pressure and gain in event-free life expectancy.

Authors:  Behrouz Kassaï; Jean-Pierre Boissel; Michel Cucherat; Florent Boutitie; François Gueyffier
Journal:  Vasc Health Risk Manag       Date:  2005

10.  The COSEHC™ Global Vascular Risk Management quality improvement program: first follow-up report.

Authors:  Carlos M Ferrario; Janae Joyner; Chris Colby; Alex Exuzides; Michael Moore; Debra Simmons; William Bestermann; Feride Frech-Tamas
Journal:  Vasc Health Risk Manag       Date:  2013-07-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.